Morgan E, Arnold M, Gini A et al (2023) Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 72(2):338–344

Article  PubMed  Google Scholar 

Gong YM, Wu CX, Zhang ML et al (2015) Colorectal cancer survival analysis in major areas in Shanghai, China. Chin Oncol 25:497–504

Google Scholar 

Goel G, Sun W (2015) Novel approaches in the management of pancreaticductal adenocarcinoma: potential promises for the future. J Hematol Oncol 8:1–16

Article  Google Scholar 

Nunez-Prado N, Compte M, Harwood S et al (2015) The coming of age of engineered multivalent antibodies. Drug Discov Today 2:588–594

Article  Google Scholar 

Spellman A, Tang SC (2016) Immunotherapy for breast cancer: past, present, and future. Cancer Metastasis Rev 35:525–546

Article  CAS  PubMed  Google Scholar 

Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD (2014) Immune modulation in cancer with antibodies. Annu Rev Med 65:185–202

Article  CAS  PubMed  Google Scholar 

Topp MS, Gökbuget N, Zugmaier G et al (2014) Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32:4134–4140

Article  CAS  PubMed  Google Scholar 

Spiess C, Zhai Q, Carter PJ (2015) Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 67:95–106

Article  CAS  PubMed  Google Scholar 

Fan D, Li W, Yang Y et al (2015) Redirection of CD4 + and CD8 + T lymphocytes via an anti-CD3× anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient derived B-ALL cells. J Hematol Oncol 8:108

Article  PubMed  PubMed Central  Google Scholar 

Wang S, Chen C, Meng Y et al (2012) Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody. Cancer Lett 325:214–219

Article  CAS  PubMed  Google Scholar 

Grugan KD, Dorn K, Jarantow SW et al (2017) Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells. MAbs 9:114–126

Article  CAS  PubMed  Google Scholar 

Tao JJ, Castel P, Radosevic-Robin N et al (2014) Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K/Akt pathway in triple-negative breast cancer. Sci Signal 7:1–19

Article  Google Scholar 

Fitzgerald JB, Johnson BW, Baum J et al (2014) MM-141, an IGF-IR- and ErbB3-dricted bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Therap 13:410–425

Article  CAS  Google Scholar 

Herbst RS, Soria JC, Kowanetz M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567

Article  CAS  PubMed  PubMed Central  Google Scholar 

You H, Ding W, Dang H et al (2011) c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 54:879–889

Article  CAS  PubMed  Google Scholar 

Sun ZJ, Wu Y, Hou WH et al (2017) A novel bispecific c-Met/PD-1 antibody with therapeutic potential in solid cancer. Oncotarget 8:29067–29079

Article  PubMed  PubMed Central  Google Scholar 

Wu Y, Yu M, Sun Z et al (2017) Generation and characterization of a bispecific antibody targeting both PD-1 and c-Met. Protein Pept Lett 24:1–8

Google Scholar 

Steinway SN, Dang H, You H et al (2015) The EGFR/ErbB3 pathway acts as a compensatory survival mechanism upon c-Met inhibition in human c-Met + hepatocellular carcinoma. PLoS ONE 10:1–16

Article  Google Scholar 

Cao HH, Cheng CY, Su T et al (2015) Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion. Mol Cancer 14:103–114

Article  PubMed  PubMed Central  Google Scholar 

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–925

Article  CAS  PubMed  Google Scholar 

Kryczek I, Zou L, Rodriguez P et al (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203:871–881

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schoffelen R, Boerman OC, Goldenberg DM et al (2013) Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer 109(4):934–942

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herbert Hurwitz T, Crocenzi J, Lohr et al (2014) A phase 1, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 x CD3 DART molecule, in patients with relapsed/refractory metastatic colorectal carcinoma. J Immunother Cancer 2(Suppl 3):P86

Article  PubMed Central  Google Scholar 

Heukers R, Altintas I, Raghoenath S et al (2014) Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles. Biomaterials 35:601–610

Article  CAS  PubMed  Google Scholar 

Su Z, Han Y, Sun Q et al (2019) Anti-MET VHH pool overcomes MET-targeted cancer therapeutic resistance. Mol Cancer Ther 18:100–111

Article  CAS  PubMed  Google Scholar 

Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89–103

Article  CAS  PubMed  Google Scholar 

Rosen LS, Goldman JW, Algazi AP et al (2017) A first-in-human phase I study of a bivalent MET antibody, emibetuzumab (LY2875358), as monotherapy and in combination with erlotinib in advanced cancer. Clin Cancer Res 23:1910–1919

Article  CAS  PubMed  Google Scholar 

Spigel DR, Ervin TJ, Ramlau RA et al (2013) Randomized Phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 31:4105–4114

Article  CAS  PubMed  PubMed Central  Google Scholar 

Merchant M, Ma X, Maun HR et al (2013) Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Nat Acad Sci 110:E2987–2996

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burgess TL, Sun J, Meyer S et al (2010) Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther 9:400–409

Article  CAS  PubMed  Google Scholar 

D’Arcangelo M, Cappuzzo F (2013) Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. Biologics 7:61–68

PubMed  PubMed Central  Google Scholar 

Gordon SR, Maute LR, Dulken BW et al (2017) PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity. Nature 545:459–499

Article  Google Scholar 

Benson DM, Bakan CE, Mishra A et al (2010) The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116:2286–2294

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karyampudi L, Lamichhane P, Krempski J et al (2016) PD-1 blunts the function of ovarian tumor-infiltrating dendritic cells by inactivating NF-κB. Cancer Res 76:239–250

Article  CAS  PubMed  Google Scholar 

Gordon SR, Maute RL, Dulken BW et al (2017) By. tumor Immun Nat 545:495–499PD-1 expression

CAS  Google Scholar 

Ilie M, Long-Mira E, Bence C et al (2016) Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 27:147–153

Article  CAS  PubMed  Google Scholar 

Mezquita L, Auclin E, Ferrara R et al (2018) Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol 4:351–357

Article  PubMed  PubMed Central  Google Scholar 

Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen G, Huang AC, Zhang W et al (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560:382–386

Article  CAS  PubMed  PubMed Central